.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR15_AtazanavirAndCobicistat.AtazanavirAndCobicistat .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR15_AtazanavirAndCobicistat.AtazanavirAndCobicistat| name: | AtazanavirAndCobicistat |
| ATC code: | J05AR15 | route: | oral |
| n-compartments | 1 |
Atazanavir/cobicistat is a fixed-dose antiretroviral combination used in the treatment of HIV-1 infection in adults and adolescents. Atazanavir is a protease inhibitor, while cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A enzymes, thereby increasing atazanavir plasma concentrations. This combination is approved for use in various national and international HIV treatment guidelines.
Pharmacokinetics reported in healthy HIV-negative adult volunteers following once-daily oral administration of fixed-dose combination tablets under fed conditions.